Basic Information
Exforge Tablet 5mg/160mg
TABLET, FILM COATED
Regulatory Information
SIN13417P
February 28, 2008
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XC09DB01
Company Information
NOVARTIS (SINGAPORE) PTE LTD
NOVARTIS (SINGAPORE) PTE LTD
Active Ingredients
Strength: 160.0mg
Detailed Information
Contraindications
**CONTRAINDICATIONS** - Known hypersensitivity to amlodipine, valsartan, to dihydropyridine derivatives, or to any of the excipients. - Severe hepatic impairment, biliary cirrhosis or cholestasis. - Severe renal impairment (GFR <30 ml/min/1.73 m2) and patients undergoing dialysis. - Pregnancy (see section PREGNANCY, LACTATION, FEMALES AND MALES OF REPRODUCTIVE POTENTIAL – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - The concomitant use of Exforge with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73m2) (see section INTERACTIONS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**INDICATIONS** Treatment of essential hypertension. Exforge is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.